FDA official says "no evidence" of Cox-2 problem

An FDA deputy commissioner said the agency has not yet decided if the problems that led to withdrawal of Merck's Vioxx means the agency also should consider whether similar drugs are a concern. "We don't have any definitive evidence" the heart-risk problem that affected the Vioxx arthritis drug also is involved in other drugs in the Cox-2 class, Janet Woodcock said at a conference of arthritis specialists.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA